| Biomarker ID | 950 |
| PMID | 22792137 |
| Year | 2012 |
| Biomarker | Mutation Status of FGF2 (FGF2+223 C>T) |
| Biomarker Basis | Mutation Based |
| Biomolecule | Mutation |
| Source | NA |
| Subjects | Humans |
| Regulation | Increased Risk of PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | OR: Multivariate Model (Stepwise Regression): 1.45 (95% CI: 0.98–2.14) Bootstrap: [1.45 (95% CI: 0.98–2.16)] |
| Effect on Pathways | Adipokine Pathway |
| Experiment | FGF2 mutation (FGF2+223 C>T) in All patients with Prostate Cancer |
| Type of Biomarker | Diagnostic |
| Cohort | A total of 449 histologically confirmed prostate cancer and 557 non-prostate cancer patients were included in the analyses. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | NA |
| Method Used | NA |
| Clinical | No |
| Remarks | For each SNP, the risk genotypes were coded as 1 and the non-risk alleles as 0. The model was determined by multiplying the b coefficient by the SNPs, plus the c coefficient by the PSA value and the a coefficient by the patient’s age (Inclusive Risk Score = S bi x Xi+c x PSA+a x Age; where Xi = SNPs scaled for risk, bi = coefficient for SNPs, c = coefficient for PSA, a = coefficient for Age). |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | FGF2 |